Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
NCT ID NCT05313243
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining two drugs—pembrolizumab (Keytruda) and brentuximab vedotin (Adcetris)—can shrink tumors in people with a type of T-cell lymphoma that has returned or not responded to at least one prior treatment. The study enrolls adults with CD30-positive T-cell lymphoma, including peripheral and cutaneous subtypes. Participants receive both drugs for up to 16 cycles, with pembrolizumab continuing for a total of 35 cycles if the disease responds. The main goal is to see how many people have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and brentuximab vedotin
What this could lead to
If successful, this combination could offer a new treatment option for people with T-cell lymphoma that has not responded to prior therapy.
What could go wrong
This is an early-phase trial with a small number of participants. The combination may cause side effects, and the hoped-for response rate may not be achieved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Smilow Cancer Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact